Rita Hyde, MD
Internal Medicine · Westwood, KSNPI 1790701084
Payments from drug & device makers
Across 76 payments — averaging $14.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$243
- Novo Nordisk$166
- Sanofi-aventis U.S. LLC$78
- Lilly USA, LLC$66
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$61
- AstraZeneca$52
- plus $464 from 15 others
What the payments were for
- Food & beverage$1,131100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 14 | $243 |
| Novo Nordisk | 11 | $166 |
| Sanofi-aventis U.S. LLC | 5 | $78 |
| Lilly USA, LLC | 5 | $66 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $61 |
| AstraZeneca | 4 | $52 |
| AbbVie | 4 | $50 |
| Johnson & Johnson | 4 | $49 |
| Pfizer | 3 | $49 |
| GSK | 3 | $42 |
| Novartis | 3 | $41 |
| Teva Pharmaceuticals USA, Inc. | 3 | $39 |
| Astellas Pharma US Inc | 2 | $37 |
| Amarin Pharma, Inc. | 2 | $31 |
| Therapeuticsmd, Inc. | 2 | $31 |
| Merck | 2 | $26 |
| Eisai Inc. | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
| Radius Health, Inc. | 1 | $12 |
How this compares
$1,131 in reported general payments places this provider in the 75th percentile of 705 internal medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 101 | $115,524 |
| OzempicSemaglutide | 93 | $101,348 |
| JardianceEmpagliflozin | 83 | $89,364 |
| JanuviaSitagliptin Phosphate | 19 | $29,877 |
| MounjaroTirzepatide | 27 | $28,690 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 14 | $14,417 |
| SynthroidLevothyroxine Sodium | 141 | $14,372 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 34 | $8,652 |
| Atorvastatin Calcium | 903 | $8,124 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $6,285 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 18 | $6,007 |
| Rosuvastatin Calcium | 503 | $5,405 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 11 | $5,161 |
| Losartan Potassium | 541 | $4,970 |
| Levothyroxine Sodium | 489 | $4,942 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Paxlovid | $49 | $116,979124 claims |
| Novo NordiskOzempic | $166 | $101,34893 claims |
| MerckJanuvia, Janumet Xr | $26 | $44,29333 claims |
| Lilly USA, LLCMounjaro | $66 | $28,69027 claims |
| GSKArexvy, Breo Ellipta | $42 | $14,93748 claims |
| AbbVieSynthroid | $50 | $14,372141 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 705 internal medicine providers in Kansas.
Other internal medicine in Westwood
- Raed Al RajabiWestwood$4.5M
- Lauren NyeWestwood$409K
- Martin KankamLeavenworth$63.4M
- Mark HamblinKansas City$5.2M
- Katherine WillinghamTopeka$4.8M
- Leslie SpikesKansas City$4.5M
- Michael CoxTopeka$3.4M
- James RuhlmannHutchinson$2.8M
- Scott TeeterTopeka$1.2M
- Shadi HamdehKansas City$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.